[Role of electrophysiology in the prognosis and therapy of cardiomyopathies].
Laurenzi
F
F
Modulo Dipartimentale di Elettrost molazione, Elettrofisiologia e Aritmologia Ospedale S. Camillo, Roma.
Avella
A
A
Adinolfi
E
E
Dini
P
P
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000517:prevention & control / Q000628:therapy; D009202:Cardiomyopathies / Q000175:diagnosis* / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D004594:Electrophysiology; D005260:Female; D005500:Follow-Up Studies; D006439:Hemodynamics; D006801:Humans; D008297:Male; D015201:Meta-Analysis as Topic; D009203:Myocardial Infarction / Q000209:etiology / Q000517:prevention & control; D011322:Primary Prevention; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D013015:Sotalol / Q000627:therapeutic use; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D014665:Vasodilator Agents; D013015:Sotalol; D000638:Amiodarone